Fitness Trends Global CAR T Cell Therapy Market | Page 2

Report includes chapters which deeply display the following deliverable about industry :
• Global CAR T Cell Therapy Market Research Objective and Assumption
• Global CAR T Cell Therapy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Global CAR T Cell Therapy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Global CAR T Cell Therapy Market, By Regions
• Global CAR T Cell Therapy Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Global CAR T Cell Therapy Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Global CAR T Cell Therapy Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global CAR T Cell Therapy Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Market Dynamics
CAR-T cell therapy is expected to be an important development in cancer treatment and
therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading
to high demand for its treatment. According to the World Cancer Research Fund International
(WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it
is projected that by 2035, around 24 million cancer cases would be observed worldwide.
Moreover, introduction of new therapies into the market is further expected to bolster growth
of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug
Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based
gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However,
risks of side effects resulting in various neurological disorders is expected to hinder growth of
the global CAR-T cell therapy market.